

Correlates of Risk for Disinhibited Behaviors in the Million Veteran Program Cohort

Peter B. Barr ^{*1-4}, Tim B. Bigdeli ^{*1-4}, Jacquelyn L. Meyers ¹⁻⁴, Roseann E. Peterson ¹⁻³, Sandra Sanchez-Roige ^{5,6}, Travis T. Mallard ^{7,8}, Danielle M. Dick ^{9,10}, K. Paige Harden ^{11,12}, Anna Wilkinson ^{13,14,15}, David P. Graham ^{13,16}, David A. Nielsen ^{13,16}, Alan Swann ^{13,16}, Rachele K. Lipsky ^{13,16}, Thomas Kosten ^{13,16}, Mihaela Aslan ^{17,18}, Philip D. Harvey ^{†19,20}, Nathan A. Kimbrel ^{†21-23}, and Jean C. Beckham ^{†21-23}, on behalf of the Million Veteran Program (MVP) and Cooperative Studies Program (CSP) #572

1. VA New York Harbor Healthcare System, Brooklyn, NY
2. Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences University, Brooklyn, NY
3. Institute for Genomics in Health (IGH), SUNY Downstate Health Sciences University, Brooklyn, NY
4. Department of Epidemiology and Biostatistics, School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, NY
5. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
6. Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
7. Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
8. Department of Psychiatry, Harvard Medical School, Boston, MA, USA
9. Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ
10. Rutgers Addiction Research Center, Rutgers University, Piscataway, NJ
11. Department of Psychology, University of Texas at Austin, Austin, TX
12. Population Research Center, University of Texas at Austin, Austin, TX
13. Michael E. DeBakey VA Medical Center, Houston, TX
14. UTHealth Houston School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX
15. Michael and Susan Dell Center for Healthy Living, The University of Texas Health Science Center at Houston, Houston, TX
16. Department of Psychiatry, Neuroscience, Pharmacology, and Immunology and Rheumatology, Baylor College of Medicine, Houston, TX
17. Clinical Epidemiology Research Center (CERC), VA Connecticut Healthcare System, West Haven, CT
18. Yale University School of Medicine, New Haven, CT
19. Research Service, Bruce W. Carter Miami Veterans Affairs (VA) Medical Center, Miami, FL
20. University of Miami Miller School of Medicine, Miami, FL
21. Durham VA Health Care System, Durham, NC
22. VA Mid-Atlantic Mental Illness Research, Education and Clinical Center, Durham, NC
23. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC

* These authors contributed equally to this work; † These authors jointly supervised this work

Corresponding author: Peter B. Barr

450 Clarkson Ave, MSC 1203, Brooklyn, NY 11203

e-mail: peter.barr@downstate.edu.

Running Header: Correlates of Externalizing Risk in Veterans

Word count abstract: 306; Word count text body: 3,897; Figures and Tables: 4 Figures

47 **ABSTRACT**

48 **Background:** Many psychiatric outcomes are thought to share a common etiological pathway reflecting
49 behavioral disinhibition, generally referred to as externalizing disorders (EXT). Recent genome-wide
50 association studies (GWAS) have demonstrated the overlap between EXT and important aspects of
51 veterans' health, such as suicide-related behaviors, substance use disorders, and other medical
52 conditions.

53 **Methods** We conducted a series of phenome-wide association studies (PheWAS) of polygenic scores
54 (PGS) for EXT, and comorbid psychiatric problems (depression, schizophrenia, and suicide attempt) in
55 an ancestrally diverse cohort of U.S. veterans ($N = 560,824$), using diagnostic codes from electronic
56 health records. We conducted ancestry-specific PheWASs of EXT PGS in the European, African, and
57 Hispanic/Latin American ancestries. To determine if associations were driven by risk for other comorbid
58 problems, we performed a conditional PheWAS, covarying for comorbid psychiatric problems
59 (European ancestries only). Lastly, to adjust for unmeasured confounders we performed a within-family
60 analysis of significant associations from the main PheWAS in full-siblings ($N = 12,127$, European
61 ancestries only).

62 **Results:** The EXT PGS was associated with 619 outcomes across all bodily systems, of which, 188
63 were independent of risk for comorbid problems of PGS. Effect sizes ranged from $OR = 1.02$ (95% CI =
64 $1.01, 1.03$) for overweight/obesity to $OR = 1.44$ (95% CI = $1.42, 1.47$) for viral hepatitis C. Of the
65 significant outcomes 73 (11.9%) and 26 (4.5%) were significant in the African and Hispanic/Latin
66 American results, respectively. Within-family analyses uncovered robust associations between EXT and
67 consequences of substance use disorders, including liver disease, chronic airway obstruction, and viral
68 hepatitis C.

69 **Conclusion:** Our results demonstrate a shared polygenic basis of EXT across populations of diverse
70 ancestries and independent of risk for other psychiatric problems. The strongest associations with EXT
71 were for diagnoses related to substance use disorders and their sequelae. Overall, we highlight the
72 potential negative consequences of EXT for health and functioning in the US veteran population.

73

74 INTRODUCTION

75 Psychiatric disorders have far-reaching consequences for affected individuals, their families,
 76 communities, and the broader society¹⁻⁴. Many of these disorders are strongly co-morbid and share, at
 77 least in part, a common etiology⁵. Disorders related to behavioral disinhibition, such as substance use
 78 disorders (SUD), conduct disorder, and antisocial personality disorder, have been labeled as
 79 externalizing disorders^{6,7}. Twin and family studies suggest that the common liability towards
 80 externalizing disorders is highly heritable (~80%)⁸⁻¹⁰. Recent multivariate genome wide association
 81 studies (GWAS) have found robust evidence for a latent genomic factor for externalizing disorders^{11,12},
 82 composed of input GWAS related to substance use disorders, risky sexual behaviors, personality
 83 characteristics, and neurodevelopmental disorders. Importantly, genetic liability for externalizing
 84 disorders overlaps with other phenotypes of public health relevance, such as suicidal thoughts and
 85 behaviors^{11,13-15}, SUDs^{11,16-18}, and a range of other medical conditions (e.g., ischemic heart disease,
 86 liver disease, viral hepatitis)¹¹. The widespread impact of risk for externalizing disorders makes it a
 87 potential target for early intervention and prevention.

88 The proliferation of large-scale biobanks – such as All of Us¹⁹, the UK Biobank²⁰, FinnGen²¹,
 89 and Biobank Japan²² – linking individual-level genomic data with electronic health records (EHRs)
 90 presents opportunities to further explore the relationships between genetic liability for a given disorder
 91 (typically in the form of polygenic scores, or PGS), and a wide range of clinical phenotypes. This
 92 hypothesis free approach, referred to as a phenome-wide association study (PheWAS)²³, can aid in
 93 identifying novel trait associations and understanding pleiotropic effects. Recent PheWAS using PGS
 94 for other psychiatric problems (e.g., schizophrenia, bipolar disorder, and depression) have identified
 95 widespread associations between PGS and a host of psychiatric and other medical diagnoses^{24,25}.

96 In the current analysis, we applied a PheWAS of a PGS derived from a multivariate GWAS of
 97 externalizing disorders/problems (EXT)¹¹ to the EHRs of the Department of Veterans Affairs Million

98 Veterans Program Cohort (MVP) ²⁶. A previous PheWAS of the EXT PGS in the Vanderbilt University
 99 Medical Center Biobank (BioVU) ²⁷ identified over 250 associations with EHR derived medical
 100 conditions ¹¹, but was limited to individuals of European ancestries. We extend the PheWAS of the EXT
 101 PGS all veterans of European, African, and Hispanic/Latin American ancestries. We further compared
 102 results from our primary PheWAS of EXT to analogously derived results for PGSs of schizophrenia
 103 (SCZ) ²⁸, depression (DEP) ²⁹, and suicide attempt ¹³, including joint modeling of these PGS. Finally, we
 104 attempted to replicate the findings from the primary PheWAS in a holdout sample of related veterans
 105 (full siblings). Genetic differences between siblings are random; therefore, within sibship associations
 106 between the EXT PGS and health outcomes cannot be attributed to between-family sources of
 107 confounding, such as environmental exposures that are correlated with population stratification.

108 **METHODS**

109 *The Million Veterans Program Cohort (MVP)*

110 Launched in 2010, MVP is a landmark endeavor that links genomic laboratory testing, survey-
 111 based self-report data, and EHRs, with the goal of creating a “mega-biobank” and evidence base for
 112 precision medicine initiatives ²⁶. The 850,000 enrolled participants reflect the population that utilizes the
 113 Veterans Health Administration (VHA), with over-representation of older and male individuals, as well
 114 as higher rates of multiple morbidities and chronic conditions related to externalizing compared to the
 115 general population ^{30,31}. Participants are active users of the VHA healthcare system and were recruited
 116 through invitational mailings or by MVP staff while receiving clinical care. Informed consent and
 117 authorization per the Health Insurance Portability and Accountability Act (HIPPA) were the only other
 118 inclusion criteria. Once enrolled, participants EHR data are linked, including diagnostic codes, routine
 119 laboratory results, and medications. The current analysis uses Release 4 of MVP data, as collection is
 120 ongoing. The present analyses were approved by the VA Central Institutional Review Board (IRB), and
 121 all participants provided written informed consent.

122 Genotyping

123 MVP participants were genotyped on the MVP 1.0 Axiom array³². Genetic ancestries of
 124 participants were classified using the HARE (harmonized ancestry and race-ethnicity) method³³, which
 125 harmonizes the closest ancestral population with self-identified race and ethnicity. Genotypic data were
 126 imputed to the Trans-Omics for Precision Medicine (TOPMed) reference panel³⁴, which specifically
 127 improves imputation quality in non-European and admixed ancestries³⁵. As of Release 4, there are
 128 467,101 veterans of predominantly European ancestries (EUR), 124,717 veterans of predominantly
 129 African ancestries (AFR), 52,416 veterans of predominantly Hispanic/Latin American ancestries (HIS),
 130 and 8,362 veterans of predominantly Asian ancestries (ASN) with available genotypic and electronic
 131 health record data. In the current analysis, we included data from the EUR, AFR, and HIS groups, as
 132 these had sufficient statistical power for the number of associations tested. Within each of these HARE
 133 categories, we restricted analyses to unrelated individuals, excluding all those who were second-
 134 degree relatives or closer (KING coefficient ≤ 0.177) and limited to those whose primary self-identified
 135 race-ethnicity matched their HARE classification, so as to not introduce potential confounding driven by
 136 well-characterized health disparities related to racism and racial discrimination^{36,37}.

137 Electronic health records (EHRs)

138 Our main outcomes for the analyses were phecodes, which are clusters of ICD-9/10-CM codes in
 139 the EHR^{38,39} and have been validated previously^{40,41}. We considered individuals as having a diagnosis
 140 for any given phecocode if there were two or more occurrences of that phecocode in their EHR. Prior
 141 analyses have shown that 2 or more phecodes as a good predictor diagnosis^{24,25}. Phecodes are
 142 grouped into 17 categories: infectious diseases, neoplasms, endocrine/metabolic, hematopoietic,
 143 mental disorders, neurological, sense organs, circulatory system, respiratory, digestive, genitourinary,
 144 pregnancy complications, dermatologic, musculoskeletal, congenital anomalies, symptoms, and injuries
 145 & poisonings. We excluded phecodes for which there were fewer than 100 cases with the diagnosis. In
 146 total, there were 1,652 phecodes, 1,436 phecodes, and 1,125 phecodes with $N \geq 100$ diagnoses
 147 available for EUR, AFR, and HIS veterans, respectively.

148 *Polygenic scores (PGS)*

149 We estimated PGSs derived from four large-scale GWASs: externalizing problems (EXT,
150 $N_{\text{effective}} = 1,492,085$)¹¹, depression (DEP, $N_{\text{effective}} = 449,856$)²⁹, schizophrenia (SCZ, $N_{\text{effective}} = 117,498$)
151 ²⁸, and suicide attempt (SUI, $N_{\text{effective}} = 91,230$)¹³. We focus on these additional PGS because: 1)
152 internalizing (e.g., depression) and thought (e.g., schizophrenia) disorders are genetically correlated
153 with EXT¹¹ and could confound associations between EXT and phenotypes of interest. 2) We included
154 the SUI PGS, specifically, to explore the possibility of suicide risk related to impulsivity and behavioral
155 disinhibition, independent of risk for specific to SUI or related to DEP. While PheWAS is an agnostic
156 approach, included the additional measures of genetic liability to explore the robustness of potential
157 associations with phenotypes of particular public health relevance to the veteran population (e.g.,
158 suicidal behaviors).

159 In EUR ancestries, we created PGS using PRS-CS⁴², a Bayesian regression and continuous
160 shrinkage method that uses an external reference panel (e.g., 1000 Genomes Phase III European
161 subsample) to estimate the posterior effect sizes for each SNP in a given set of GWAS summary
162 statistics. In the AFR and HIS ancestries, we used a different approach. PGS accuracy decays
163 continuously as target samples differ in ancestry from the discovery GWAS, even within relatively
164 homogenous genetic clusters⁴³ and we lacked ancestry-matched GWAS for EXT to use methods that
165 boost power of PGS in underpowered samples, such as PRS-CSx⁴⁴. Therefore, in the AFR and HIS
166 ancestries, we created EXT PGS using the 579 loci reported in the externalizing GWAS, as using
167 genome wide significant variants is more robust to population stratification⁴⁵. We standardized all PGS
168 to Z-scores.

169 *Analytic plan*

170 We first conducted a phenome-wide association study (PheWAS) to examine the association
171 between the EXT PGS and 1,652 phecodes within EUR ancestries, using logistic regression and
172 covarying for age, sex, and twenty ancestry principal components (PCs). We also conducted the same
173 PheWAS for the DEP, SCZ, and SUI PGSs to compare the overlap of significant associations from the

four independent PheWAS. Next, we attempted to replicate any phenome-wide significant associations within AFR and HIS ancestries. Third, we performed a conditional PheWAS, including all PGS in the same model, to test whether associations between EXT remained while controlling for DEP, SCZ, and SUI PGSs. We also co-varied for total comorbidity burden, created by tabulating the number of unique phecode terms for which an individual met criteria for the 600 top parent codes, and then transforming this count using an inverse normal transformation²⁵. Lastly, to control for additional confounders, we used a subset of full siblings ($N = 12,127$) identified through genetic data, to test for associations between EXT and phecodes within-family. For within-family models, we used a linear probability model as opposed to logistic regression, as the fixed effects logistic regression can provide biased estimates when the number of observations per group is small⁴⁶. We applied a multiple testing correction for 1,652 tests across the 4 PGS included in the analyses for EUR ancestries ($p < .05/6608 = p < 7.57 \times 10^{-4}$). We used a less conservative approach to multiple testing in the AFR and HIS ancestries given the expected reduction in predictive power of PGS, applying a false discovery rate (FDR)⁴⁷ of 5%.

RESULTS

Main PheWAS of EXT PGS

Of the 467,101 veterans of broadly European ancestries (EUR), we filtered down to a sample of 438,384 unrelated individuals. After removing those with any missing information, those without available EHR data, and retaining those whose primary identity was Non-Hispanic White, $N = 406,254$ participants were available for the initial PheWAS in EUR (mean age = 69.8, SD = 14.1; 92.8% male). We performed a similar process for veterans of African (AFR, $N = 112,390$, mean age = 63.5, SD = 12.6; 86.3% male) and Hispanic/Latin American (HIS, $N = 42,179$, mean age = 60.5, SD = 16.2; 90.4% male) ancestries. eTable 1 presents all demographic statistics.

Of the 1,652 total phecodes we tested, 619 (37.5%) were significantly associated with EXT PGS after correcting for multiple testing. We observed significant associations for EXT PGS across all virtually all bodily systems, with the strongest positive associations being between EXT PGS and *viral*

199 *hepatitis C* (OR = 1.49; 95% CI = 1.46, 1.51), *substance addiction and disorders* (OR = 1.39; 95% CI =
200 1.37, 1.40), *embolism/thrombosis of the abdominal aorta* (OR = 1.36; 95% CI = 1.22, 1.51), *tobacco*
201 *use disorders* (OR = 1.35; 95% CI = 1.34, 1.36), and *cancer of the mouth* (OR = 1.33; 95% CI = 1.17,
202 1.50). We also observed robust negative associations with *autism* (OR = 0.76; 95% CI = 0.68, 0.86),
203 *intestinal infection* (OR = 0.85; 95% CI = 0.80, 0.90), *disorders of bilirubin excretion* (OR = 0.90; 95% CI
204 = 0.86, 0.94), and *prostate cancer* (OR = 0.97; 95% CI = 0.95, 0.98).

205 Figure 1, Panel A presents the distribution in EXT effect sizes (odds ratios, ORs) for all 619
206 significant PheWAS associations by phecode domain. Across domain, there is a general enrichment for
207 positive associations with EXT: the median effect sizes are generally above one and greater levels of
208 EXT risk are generally associated with increased risk of diagnoses. The one exception is pregnancy
209 complications, which had no significant associations and is not unexpected given the predominantly
210 male composition of this study sample. While there was variation in effect sizes across groupings of
211 phecodes, the largest associations, on average, were for phecodes related to respiratory issues, mental
212 disorders, injuries & poisonings, and infectious diseases (median ORs = 1.12 – 1.14).

213 Lastly Panel B presents the breakdown of independent phenome-wide significant associations
214 across the EXT, DEP, SCZ and SUI PGS^{48,49}. Across all the 6,608 tests (4 PGS with 1,652 phecodes),
215 779 (11.78%) of the associations had p-values below the Bonferroni corrected threshold ($p < 7.58 \times 10^{-4}$).
216 The majority of these associations (56.1 %, N = 437) involved three of the four PGSs, and over 70%
217 (N = 561) involved two or more of the PGSs. The full results are in eTable 2.

218 *Multi-Ancestry Verification of EXT PGS*

219 We next examined whether EXT PGS associations that were significant in the main EUR
220 analyses were comparable in the AFR and HIS MVP participants. Among the 619 significant
221 associations in veterans of EUR ancestries, 614 were available ($N_{DX} \geq 100$) and 73 (11.9%) were
222 significant in veterans of AFR ancestries, 584 were available and 26 (4.5%) were significant in veterans
223 of HIS ancestries after correcting for multiple testing. Panel A in Figure 2 presents the proportion of
224 significant association identified in the EUR PheWAS that replicated in either AFR or HIS ancestries, by

225 phecode domain. Of all the domains, phecodes related to *mental disorders* had the highest of
 226 proportion of associations that replicated across ancestry (~25%). Panel B includes a subset of these
 227 replicated associations, which included SUDs (alcohol, tobacco, and other substances), viral hepatitis,
 228 and problems related to the respiratory system (e.g., cancer, chronic airway obstruction, and respiratory
 229 failure). As expected, while these associations were significant, there was a large attenuation in effect
 230 sizes, consistent with using PGS derived from ancestries that differ from the target sample^{44,45} (full
 231 results in eTable 3).

232 *Joint PheWAS of EXT, DEP, SCZ, and SUI PGSs*

233 Next, we investigated whether the 619 phecodes associated with EXT PGS remained
 234 associated in models after conditioning on the DEP, SCZ, and SUI PGS. Of the 619 associations with
 235 EXT, 494 (79.8%) remained associated after conditioning on the other PGS and correcting for multiple
 236 testing ($p < .05/619 = p < 8.08 \times 10^{-5}$). Effect sizes ranged from 1.02 for overweight/obesity (phecode =
 237 278; 95% CI = 1.01, 1.03) to 1.44 for viral hepatitis C (phecode 070.3; 95% CI = 1.42, 1.47) for traits
 238 positively related to the EXT PGS. Effect sizes for negative associations ranged from 0.74 for a
 239 diagnosis of autism (phecode = 313.3; 95% CI = 0.65, 0.84) to 0.97 for melanomas of the skin
 240 (phecode = 172.1; 95% CI = 0.96, 0.99). Associations that were no longer significant spanned all bodily
 241 systems, and included schizophrenia, rheumatoid arthritis, and chronic sinusitis, among many others.
 242 The median OR for the EXT PGS dropped from 1.10 in the marginal associations with these phecodes
 243 to 1.08 after conditioning on the other PGSs. Figure 2B presents a subset of the larger associations
 244 (OR >1.15, full results in Supplementary Table 4). While there was attenuation in effect sizes, EXT
 245 remained associated with the various phecodes independent of risk for DEP, SCZ, or SUI.

246 To examine whether EXT was associated with any of the 619 outcomes due to the increased
 247 number of comorbidities associated with higher levels of externalizing, we ran the PheWAS including a
 248 covariate for total comorbidity burden in veterans of European ancestries. Figure 3, Panel B includes
 249 box plots for the main PheWAS (EXT PGS only), the conditional PheWAS (EXT, DEP, SCZ, and SUI
 250 PGSs), and the model with all PGSs and the comorbidity score. There is an attenuation in median

effect size across each set of analyses. Of the 619 significant associations identified in the main PheWAS, 188 remained associated with EXT after adjusting for total comorbidity burden and the additional PGSs, with the top associations remaining those for viral hepatitis, substance use disorders, and complications from smoking (full results in eTable 5). Of these 188 scores, 181 (96%) were not phenotypes directly related to EXT (e.g., SUDs) and 165 (88%) were outside the domain of *mental disorders*.

Within-family replication of Main PheWAS Results

Finally, we investigated the 494 phecodes that remained significantly associated with EXT in the conditional PheWAS using a sample of full siblings from the broader MVP ($N = 12,127$). Of these 494 phecodes, 439 had available information in the subset of related veterans. Within these remaining 439 associations, 77 were marginally significant ($p < .05$) but only 13 of these associations remained after correcting for multiple testing using a false discovery rate (FDR) of 5%. Though many of the SUD phecodes were strongly associated in the main PheWAS and marginally significant in the within-family associations, only the tobacco use disorders association survived corrections for multiple testing ($\beta_{within} = 0.049$, $p < 1.28 \times 10^{-7}$, see eTable 6 for full results).

Interestingly, the associations that remained significant within-family were overwhelmingly related to downstream consequences of various forms of substance use, including viral hepatitis C, chronic liver disease and cirrhosis, chronic airway obstruction, and ischemic heart disease. Figure 3 shows the relative effect sizes from the linear probability models with (ordinary least squares, or OLS) and without (within-family) family fixed-effects. For some of the associations we see a marked decrease in effect size. Therefore, a non-trivial portion of the association between the EXT PGS and these phenotypes may be due to some type of confounding. However, for viral hepatitis C, tobacco use disorder, and chronic airway obstruction, there is little or no attenuation, and these estimates could reflect some type of causal pathway between underlying risk and disease state.

275 DISCUSSION

276 Problems related to behavioral disinhibition, commonly referred to as externalizing, may have
 277 detrimental consequences for health and well-being. We and others have shown that risk for EXT
 278 disorders overlaps with a variety of key public health outcomes at both the genetic and phenotypic level
 279 ^{11,13–18,50}. In the current analysis, we leveraged these recent, novel insights into the underlying genetic
 280 basis of EXT, extended analyses to multiple ancestries, and evaluated their correlates in the largest
 281 integrated healthcare system in the US.

282 As expected, some of the strongest associations across all of the model specifications were in
 283 the phecode domain of *mental disorders*. Specifically, substance use disorders (alcohol, tobacco, and
 284 other substances) were among the strongest associations, though other psychiatric problems, including
 285 conduct disorder, personality disorders, and attention deficit/hyperactivity disorder (ADHD) were also
 286 associated. Some components, specifically problematic alcohol use, smoking, and ADHD, contributed
 287 to the multivariate GWAS used for creating the EXT PGS ¹¹, but analyses in the original EXT paper
 288 showed that the latent factor was not driven by any single indicator, so it is unlikely that associations
 289 are driven any indicator-outcome similarity. Overall, these associations help to validate the EXT PGS
 290 within MVP and further demonstrate the utility of focusing on shared risk across psychiatric conditions⁷.

291 Results from the main PheWAS also replicated the diversity of bodily systems that were
 292 associated with risk for externalizing disorders ¹¹. For example, the EXT PGS remained associated
 293 with suicide-related phecodes (suicidal ideation, suicide attempt, and self-harm) even when
 294 conditioning on the suicide PGS and other comorbidities, suggesting that the association between
 295 externalizing and suicidal behaviors is independent of risk for the other forms of psychiatric problems
 296 (e.g., depression), supporting the role of impulsivity in suicide risk ⁵¹. In total, 181 (~96%) of the
 297 associations that survived correction for multiple testing and covarying for other PGS and comorbidities
 298 were phenotypes traditionally used to measure externalizing (e.g., ADHD, SUDs). Overall, these results
 299 point to a robust pathway between risk for externalizing disorders and numerous medical conditions

that: 1) replicated across ancestry, 2) was not explained by risk for other common forms of psychiatric problems, and 3) could not be fully explained by documented comorbidities.

The EXT PGS was associated with *reduced* risk for 6 phecodes: prostate cancer, melanoma, disorders of bilirubin excretion, autism, celiac disease, and flat foot. While associations may reflect a true reduced risk, the negative associations may also reflect our use of lifetime diagnosis. Because several of these diseases are strongly age-graded, supposedly protective associations may reflect bias due to mortality selection. Future work can leverage the longitudinal EHR data in MVP to characterize the association between and early mortality to determine whether there is any true protective effect.

The expansive MVP cohort allowed us the opportunity to explore the possibility of confounding influences via a *novel* approach: leveraging an appreciable number of full-siblings that comprise less than 2% of the overall cohort. The within-family analyses presented an additional test of whether EXT is simply a correlate or potentially causally related to various phecodes. In the holdout sample of full siblings, only a portion of the associations (13/439, 3.0%) remained associated after correcting for multiple testing. While suicide ideation, attempt and self-harm was one of the stronger associations in the PheWAS, it did not replicate on a within-family basis. This may have been due to the relatively few cases of suicidal ideation, attempt or self-harm in the EHR of the smaller within-family sample (n = 205, 1.7%). In terms of SUDs, only tobacco use disorders remained significant after multiple testing correction, though alcohol related disorders (phecode 317) was marginally significant. There was insufficient within-family variation to include substance and addiction disorders (phecode 316) in the within-family models. Moreover, many of the associations that replicated within-family were likely *consequences* of SUDs. These included chronic airway obstruction (smoking-related), chronic liver disease and cirrhosis (alcohol-related), and viral hepatitis C (intravenous drug use related). The within-family associations point to the potential causal impact of risk for externalizing on these medical conditions, likely mediated through SUDs. It is important to note that even though within-family associations are robust to confounding, they can be biased in the presence of genetic nurture and sibling effects⁵².

326 It is important to note that even though we detected a large number of significant associations
327 with the EXT polygenic score, many of the effect sizes are too small to be clinically relevant. The utility
328 of polygenic scores in clinical settings is an ongoing discussion^{53,54}. Recent work in substance use
329 disorders has shown that PGS are not sufficiently powered to meaningfully identify individuals at
330 increased risk of developing SUDs⁵⁵, especially when well-known social or clinical risk factors are
331 included in the same model⁵⁰.

332 Our analysis has several important limitations. First, although we included large samples of
333 multiple ancestries, PGS were derived from a GWAS of primarily European ancestries. Consistent with
334 recent observations of other PGS in MVP²⁵, the EXT PGS was associated with many of the traits within
335 the AFR and HIS samples, but the effect sizes were highly attenuated. Large-scale discovery GWAS in
336 diverse cohorts are vital to ensuring that PGS perform as well in these groups and that any benefit of
337 precision medicine is shared equitably across the population⁵⁶. Second, results from this sample may
338 not be generalizable to the broader U.S. population. While generally representative of the VA, MVP is
339 still a selected subset comprising primarily male individuals. Additional work is needed to ensure that
340 the study results generalize beyond the VA. Third, we did not examine PGS in conjunction with social
341 and environmental factors. Both polygenic and environmental risk factors are important for
342 understanding key outcomes in veterans' health, including substance use disorders⁵⁰, major
343 depressive disorder⁵⁷, and other mental health problems⁵⁸. Many veterans are at risk for adverse
344 environmental experiences due to poverty, minority status, and physical and psychiatric challenges⁵⁹.
345 Future work should endeavor to move beyond the focus on genetic or environmental risk in isolation
346 and towards integrated approaches. Lastly, while our results are largely robust to additional confounds
347 and replicate within-family, we cannot completely rule out non-causal reasons for the observed
348 associations.

349 Risk for externalizing disorders is correlated to many outcomes of serious public health concern.
350 A predisposition towards greater levels of externalizing is associated with increased risk of substance
351 use disorders, suicide related behaviors, and other chronic medical conditions. Our analysis

352 demonstrated that externalizing risk is equally important among the US veteran population who receive
353 their healthcare within the VA system. Intervention and prevention efforts that identify ways to target
354 and monitor the behavioral manifestations of externalizing risk (e.g., improving impulse control) could
355 substantially improve morbidity and mortality outcomes.

356

357 **ACKNOWLEDGEMENTS**

358 The views expressed in this article are those of the authors, and do not necessarily reflect the position
 359 or policy of the Department of Veterans Affairs (VA). The Million Veteran Program (MVP) is funded by
 360 grant #MVP000 from the VA Office of Research and Development (ORD). This work was also funded
 361 by grant #1I01CX001729 from the Clinical Services Research & Development (CSRDP) Service of VA
 362 ORD to Drs. Beckham and Kimbrel, by the MVP CHAMPION program, which is a collaboration
 363 between the VA and the Department of Energy (DoE), and by a CSRDP Senior Research Scientist
 364 award (IK6BX003777) to Dr. Beckham. Drs. Barr, Bigdeli, Aslan, and Harvey are supported by VA
 365 Cooperative Studies Program (CSP) #572. Drs. Peterson, Bigdeli, and Meyers are supported by the
 366 National Institute of Mental Health (R01MH125938). Dr. Peterson is also supported by the National
 367 Institute on Alcohol Abuse and Alcoholism (P50AA022537) and the Brain Behavior Research
 368 Foundation NARSAD grant 28632 PS Fund. Drs. Barr and Dick are also supported by the National
 369 Institute of Drug Abuse (R01DA050721) and the National Institute of Alcohol Abuse and Alcoholism
 370 (R01AA015416). Dr. Sanchez-Roige was supported by funds from the California Tobacco-Related
 371 Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226) and the National
 372 Institute on Drug Abuse (DP1DA054394). Dr. Mallard is supported by funds from NIH T32HG010464.
 373 The content is solely the responsibility of the authors and does not necessarily represent the official
 374 views of the National Institutes of Health. Dr. Barr had full access to all the data in the study and takes
 375 responsibility for the integrity of the data and the accuracy of the data analysis.

376

377 We would also like to thank The Externalizing Consortium for sharing the GWAS summary statistics of
 378 externalizing. The Externalizing Consortium: Principal Investigators: Danielle M. Dick, Philipp
 379 Koellinger, K. Paige Harden, Abraham A. Palmer. Lead Analysts: Richard Karlsson Linnér, Travis T.
 380 Mallard, Peter B. Barr, Sandra Sanchez-Roige. Significant Contributors: Irwin D. Waldman. The
 381 Externalizing Consortium has been supported by the National Institute on Alcohol Abuse and
 382 Alcoholism (R01AA015416 -administrative supplement), and the National Institute on Drug Abuse

383 (R01DA050721). Additional funding for investigator effort has been provided by K02AA018755,
 384 U10AA008401, P50AA022537, as well as a European Research Council Consolidator Grant (647648
 385 EdGe to Koellinger). The content is solely the responsibility of the authors and does not necessarily
 386 represent the official views of the above funding bodies. The Externalizing Consortium would like to
 387 thank the following groups for making the research possible: 23andMe Inc., Add Health, Vanderbilt
 388 University Medical Center's BioVU, Collaborative Study on the Genetics of Alcoholism (COGA), the
 389 Psychiatric Genomics Consortium's Substance Use Disorders working group, UK10K Consortium, UK
 390 Biobank, and Philadelphia Neurodevelopmental Cohort. We would like to thank the many studies that
 391 made these consortia possible, the researchers involved, and the participants in those studies, without
 392 whom this effort would not be possible. We would also like to thank the research participants and
 393 employees of 23andMe.

394

395 Most importantly, we would like to thank the U.S. Veteran participants in MVP for their service, and for
 396 their time, samples, and continued participation in VA research. Without them, this work would not be
 397 possible.

398

399

REFERENCES

1. Ferrari A. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry*. 2022;9(2):137-150. doi:10.1016/S2215-0366(21)00395-3
2. Murray CJL, Mokdad AH, Ballestros K, et al. The state of US health, 1990-2016: Burden of diseases, injuries, and risk factors among US states. *JAMA - Journal of the American Medical Association*. 2018;319(14):1444-1472. doi:10.1001/jama.2018.0158
3. Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. *The Lancet*. 2017;389(10082):1885-1906. doi:https://doi.org/10.1016/S0140-6736(17)30819-X
4. Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Psychiatry*. 2018;5(12):987-1012. doi:10.1016/S2215-0366(18)30337-7
5. Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in common disorders of the brain. *Science (1979)*. 2018;360(6395):eaap8757. doi:10.1126/science.aap8757
6. Achenbach TM. The classification of children's psychiatric symptoms: a factor-analytic study. *Psychol Monogr*. 1966;80(7):1-37. doi:10.1037/H0093906
7. Kotov R, Cicero DC, Conway CC, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP) in psychiatric practice and research. *Psychol Med*. 2022;52(9):1666-1678. doi:10.1017/S0033291722001301
8. Hicks BM, Krueger RF, Iacono WG, McGue M, Patrick CJ. Family transmission and heritability of externalizing disorders: A Twin-Family Study. *Arch Gen Psychiatry*. 2004;61(9):922-928. doi:10.1001/archpsyc.61.9.922

- 425 9. Krueger RF, Hicks BM, Patrick CJ, Carlson SR, Iacono WG, McGue M. Etiological
426 connections among substance dependence, antisocial behavior and personality: Modeling the
427 externalizing spectrum. *J Abnorm Psychol.* 2002;111(3):411-424. doi:10.1037//0021-
428 843x.111.3.411
- 429 10. Barr PB, Dick DM. The Genetics of Externalizing Problems. *Curr Top Behav Neurosci.*
430 2020;47:93-112. doi:10.1007/7854_2019_120
- 431 11. Karlsson Linnér R, Mallard TT, Barr PB, et al. Multivariate analysis of 1.5 million people identifies
432 genetic associations with traits related to self-regulation and addiction. *Nat Neurosci.* Published
433 online 2021:1-10. doi:10.1038/s41593-021-00908-3
- 434 12. Baselmans B, Hammerschlag AR, Noordijk S, et al. The Genetic and Neural Substrates of
435 Externalizing Behavior. *Biological Psychiatry Global Open Science.* 2022;2(4):389-399.
436 doi:10.1016/j.bpsgos.2021.09.007
- 437 13. Mullins N, Kang JE, Campos AI, et al. Dissecting the Shared Genetic Architecture of Suicide
438 Attempt, Psychiatric Disorders, and Known Risk Factors. *Biol Psychiatry.* 2022;91(3):313-327.
439 doi:10.1016/j.biopsych.2021.05.029
- 440 14. Johnson EC, Aliev F, Meyers JL, et al. Associations between Suicidal Thoughts and Behaviors
441 and Genetic Liability for Cognitive Performance, Depression, and Risk-Taking in a High-Risk
442 Sample. *Complex Psychiatry.* 2021;7(1-2):34-44. doi:10.1159/000517169
- 443 15. Bigdeli T, Barr PB, Rajeevan N, et al. Correlates of suicidal behaviors and genetic risk among
444 United States veterans with schizophrenia or bipolar I disorder. *medRxiv.* Published online
445 March 8, 2023:2023.03.06.23286866. doi:10.1101/2023.03.06.23286866
- 446 16. Kranzler HR, Zhou H, Kember RL, et al. Genome-wide association study of alcohol consumption
447 and use disorder in 274,424 individuals from multiple populations. *Nat Commun.*
448 2019;10(1):1499. doi:10.1038/s41467-019-09480-8

- 449 17. Demontis D, Rajagopal VM, Thorgeirsson TE, et al. Genome-wide association study implicates
450 CHRNA2 in cannabis use disorder. *Nat Neurosci.* 2019;22(7):1066-1074. doi:10.1038/s41593-
451 019-0416-1
- 452 18. Deak JD, Clark DA, Liu M, et al. Alcohol and nicotine polygenic scores are associated with the
453 development of alcohol and nicotine use problems from adolescence to young adulthood.
454 *Addiction.* 2022;117(4):1117-1127. doi:10.1111/add.15697
- 455 19. The All of Us Research Program Investigators. The “All of Us” Research Program. *New England*
456 *Journal of Medicine.* 2019;381(7):668-676. doi:10.1056/nejmsr1809937
- 457 20. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and
458 genomic data. *Nature.* 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z
- 459 21. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped
460 isolated population. *Nature 2023 613:7944.* 2023;613(7944):508-518. doi:10.1038/s41586-022-
461 05473-8
- 462 22. Nagai A, Hirata M, Kamatani Y, et al. Overview of the BioBank Japan Project: Study design and
463 profile. *J Epidemiol.* 2017;27(3):S2-S8. doi:10.1016/j.je.2016.12.005
- 464 23. Denny JC, Ritchie MD, Basford MA, et al. PheWAS: Demonstrating the feasibility of a phenome-
465 wide scan to discover gene-disease associations. *Bioinformatics.* 2010;26(9):1205-1210.
466 doi:10.1093/bioinformatics/btq126
- 467 24. Zheutlin AB, Dennis J, Linnér RK, et al. Penetrance and pleiotropy of polygenic risk scores for
468 schizophrenia in 106,160 patients across four health care systems. *American Journal of*
469 *Psychiatry.* 2019;176(10):846-855. doi:10.1176/appi.ajp.2019.18091085
- 470 25. Bigdeli TB, Voloudakis G, Barr PB, et al. Penetrance and Pleiotropy of Polygenic Risk Scores for
471 Schizophrenia, Bipolar Disorder, and Depression among Adults in the US Veterans Affairs
472 Health Care System. *JAMA Psychiatry.* 2022;79(11):1092-1101.
473 doi:10.1001/jamapsychiatry.2022.2742

- 474 26. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study
475 genetic influences on health and disease. *J Clin Epidemiol*. 2016;70:214-223.
476 doi:10.1016/j.jclinepi.2015.09.016
- 477 27. Davis L. Psychiatric Genomics, Phenomics, and Ethics Research In A 270,000-Person Biobank
478 (BioVU). *European Neuropsychopharmacology*. 2019;29:S739-S740.
479 doi:10.1016/J.EURONEURO.2017.06.069
- 480 28. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic
481 biology in schizophrenia. *Nature*. 2022;604(7906):502-508. doi:10.1038/s41586-022-04434-5
- 482 29. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies
483 102 independent variants and highlights the importance of the prefrontal brain regions. *Nat*
484 *Neurosci*. 2019;22(3):343-352. doi:10.1038/s41593-018-0326-7
- 485 30. Kramarow EA, Pastor PN. The health of male veterans and nonveterans aged 25-64: United
486 States, 2007-2010. *NCHS Data Brief*. 2012;(101):1-8.
- 487 31. Boersma P, Cohen RA, Zelaya CE, Moy E. Multiple Chronic Conditions Among Veterans and
488 Nonveterans: United States, 2015-2018. *Natl Health Stat Report*. 2021;(153):1-13. Accessed
489 March 28, 2022. <https://europaepmc.org/article/med/33663648>
- 490 32. Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality Control in the
491 Million Veteran Program. *Am J Hum Genet*. 2020;106(4):535-548.
492 doi:10.1016/j.ajhg.2020.03.004
- 493 33. Fang H, Hui Q, Lynch J, et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in
494 Genome-wide Association Studies. *Am J Hum Genet*. 2019;105(4):763-772.
495 doi:10.1016/j.ajhg.2019.08.012
- 496 34. Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from the NHLBI
497 TOPMed Program. *Nature*. 2021;590(7845):290-299. doi:10.1038/s41586-021-03205-y
- 498 35. Kowalski MH, Qian H, Hou Z, et al. Use of >100,000 NHLBI Trans-Omics for Precision Medicine
499 (TOPMed) Consortium whole genome sequences improves imputation quality and detection of

500 rare variant associations in admixed African and Hispanic/Latino populations. *PLoS Genet.*
501 2019;15(12):e1008500. doi:10.1371/journal.pgen.1008500

502 36. Williams DR, Sternthal M. Understanding racial-ethnic disparities in health: sociological
503 contributions. *J Health Soc Behav.* 2010;51 Suppl(1 suppl):S15-27.
504 doi:10.1177/0022146510383838

505 37. Williams DR, Mohammed SA. Discrimination and racial disparities in health: evidence and
506 needed research. *J Behav Med.* 2009;32(1):20-47. doi:10.1007/s10865-008-9185-0

507 38. Denny JC, Bastarache L, Ritchie MD, et al. Systematic comparison of phenome-wide association
508 study of electronic medical record data and genome-wide association study data. *Nat Biotechnol.*
509 2013;31(12):1102-1110. doi:10.1038/nbt.2749

510 39. Wu P, Gifford A, Meng X, et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: Workflow
511 development and initial evaluation. *J Med Internet Res.* 2019;21(11):1-13. doi:10.2196/14325

512 40. Wei WQ, Teixeira PL, Mo H, Cronin RM, Warner JL, Denny JC. Combining billing codes, clinical
513 notes, and medications from electronic health records provides superior phenotyping
514 performance. *Journal of the American Medical Informatics Association.* 2016;23(e1):20-27.
515 doi:10.1093/jamia/ocv130

516 41. Wei WQ, Bastarache LA, Carroll RJ, et al. Evaluating phecodes, clinical classification software,
517 and ICD-9-CM codes for phenome-wide association studies in the electronic health record. *PLoS*
518 *One.* 2017;12(7):e0175508.

519 42. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and
520 continuous shrinkage priors. *Nat Commun.* 2019;10(1):1776. doi:10.1038/s41467-019-09718-5

521 43. Ding Y, Hou K, Xu Z, et al. Polygenic scoring accuracy varies across the genetic ancestry
522 continuum. *Nature* 2023. Published online May 17, 2023:1-8. doi:10.1038/s41586-023-06079-4

523 44. Ruan Y, Lin YF, Feng YCA, et al. Improving polygenic prediction in ancestrally diverse
524 populations. *Nat Genet.* 2022;54(5):573-580. doi:10.1038/s41588-022-01054-7

- 525 45. Sohail M, Maier RM, Ganna A, et al. Polygenic adaptation on height is overestimated due to
526 uncorrected stratification in genome-wide association studies. *Elife*. 2019;8.
527 doi:10.7554/eLife.39702
- 528 46. Stammann A, Heiss F, McFadden D. Estimating Fixed Effects Logit Models with Large Panel
529 Data. In: *Beiträge Zur Jahrestagung Des Vereins Für Socialpolitik 2016: Demographischer*
530 *Wandel - Session: Microeconometrics, No. G01-V3*. Beiträge zur Jahrestagung des Vereins für
531 Socialpolitik 2016: Demographischer Wandel - Session: Microeconometrics. ZBW - Deutsche
532 Zentralbibliothek für Wirtschaftswissenschaften, Leibniz-Informationszentrum Wirtschaft; 2016:1-
533 40. <http://hdl.handle.net/10419/145837>
- 534 47. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
535 Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*.
536 1995;57(1):289-300. <http://www.jstor.org/stable/2346101>
- 537 48. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting
538 sets and their properties. *Bioinformatics*. 2017;33(18):2938-2940.
539 doi:10.1093/BIOINFORMATICS/BTX364
- 540 49. Lex A, Gehlenborg N, Strobel H, Vuilleumot R, Pfister H. UpSet: Visualization of Intersecting
541 Sets. *IEEE Trans Vis Comput Graph*. 2014;20(12):1983-1992. doi:10.1109/TVCG.2014.2346248
- 542 50. Barr PB, Driver MN, Kuo SIC, et al. Clinical, environmental, and genetic risk factors for
543 substance use disorders: characterizing combined effects across multiple cohorts. *Mol*
544 *Psychiatry*. 2022;27(11):4633-4641. doi:10.1038/s41380-022-01801-6
- 545 51. Gvion Y, Levi-Belz Y, Hadlaczky G, Apter A. On the role of impulsivity and decision-making in
546 suicidal behavior. *World J Psychiatry*. 2015;5(3):255. doi:10.5498/WJP.V5.I3.255
- 547 52. Fletcher J, Wu Y, Li T, Lu Q. Interpreting Polygenic Score Effects in Sibling Analysis. *bioRxiv*.
548 Published online July 17, 2021:2021.07.16.452740. doi:10.1101/2021.07.16.452740
- 549 53. Lewis CM, Vassos E. Polygenic risk scores: From research tools to clinical instruments. *Genome*
550 *Med*. 2020;12(1):1-11. doi:10.1186/s13073-020-00742-5

551 54. Wray NR, Lin T, Austin J, et al. From Basic Science to Clinical Application of Polygenic Risk
552 Scores: A Primer. *JAMA Psychiatry*. 2021;78(1):101-109. doi:10.1001/jamapsychiatry.2020.3049

553 55. Barr PB, Ksinan A, Su J, et al. Using polygenic scores for identifying individuals at increased risk
554 of substance use disorders in clinical and population samples. *Transl Psychiatry*.
555 2020;10(1):196. doi:10.1038/s41398-020-00865-8

556 56. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic
557 risk scores may exacerbate health disparities. *Nat Genet*. 2019;51(4):584-591.
558 doi:10.1038/s41588-019-0379-x

559 57. Coleman JRI, Peyrot WJ, Purves KL, et al. Genome-wide gene-environment analyses of major
560 depressive disorder and reported lifetime traumatic experiences in UK Biobank. *Mol Psychiatry*.
561 2020;25(7):1430-1446. doi:10.1038/s41380-019-0546-6

562 58. Choi KW, Wilson M, Ge T, et al. Integrative analysis of genomic and exposomic influences on
563 youth mental health. *J Child Psychol Psychiatry*. 2022;63(10):1196-1205.
564 doi:10.1111/jcpp.13664

565 59. Meffert BN, Morabito DM, Sawicki DA, et al. US Veterans Who Do and Do Not Utilize Veterans
566 Affairs Health Care Services: Demographic, Military, Medical, and Psychosocial Characteristics.
567 *Prim Care Companion CNS Disord*. 2019;21(1):26992. doi:10.4088/PCC.18m02350
568
569

FIGURE CAPTIONS



Figure 1: PheWAS of Externalizing Polygenic Risk in MVP. PheWAS associations with EXT PGS in veterans of the primarily European ancestries (N = 406, 254). Panel A presents the box plots of effect sizes (odds ratios, OR) for the 619 (out of 1,652) significant PheWAS associations below the Bonferroni corrected p-value threshold ($p < 7.57 \times 10^{-6}$). Panel B presents an upset plot of overlap between phenome wide significant associations ($p < 7.57 \times 10^{-6}$) across all four PGS (EXT, DEP, SCZ, and SUI).

Figure 2: Multi-Ancestry Results for Externalizing Polygenic Risk in MVP. Overlap in associations across European (EUR), African (AFR), and Hispanic/Latin American (HIS) ancestries. Panel A present the proportion of PGS identified in EUR ancestries that were significant in the AFR and HIS groupings, by phecode domain. Numbers in parentheses represent the total number of significant associations in EUR, per phecode domain. Panel B presents selected associations and corresponding effect sizes (odds ratios, OR) of EXT PGS associations that replicated in either African or Hispanic/Latin American ancestry groups.



Figure 3: Associations between EXT PGS and Selected Phecodes Accounting for DEP, SCZ, and SUI PGS. Panel A presents selected associations and their corresponding effect sizes from conditional PheWAS (EXT + DEP, SCZ, and SUI PGS) in veterans of primarily European ancestries (N = 406, 254) compared to models with the EXT PGS only (marginal). Panel B presents box plots for the effect sizes from the 619 significant associations identified in the main PheWAS in: 1) the PheWAS of EXT PGS only; 2) the PheWAS of EXT and other PGSS; and 3) the PheWAS of EXT, other PGSSs, and the total comorbidity score.

Figure 4: Change in Effect Sizes for EXT PGS in Within-family Models. Change in effect sizes for significant associations in a sample of related veterans of primarily European ancestries (N = 12,127). Estimates represent the change between ordinary least squares models (with clustered standard


596 errors) and family fixed effects models. All associations significant after correcting for a false discovery
597 rate (FDR) of 5%.



A Proportion of Overlap with Phenomewide Significant Associations by Domain (N = 619)



A



B

